Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Correctional Facilities

Distribution of COVID-19 Monoclonal Antibody Therapeutics

State and local correctional facilities, including prisons and jails, can provide monoclonal antibody (mAb) therapy for non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. These treatments are indicated for eligible patients 12 years and older with a high risk of progressing to severe forms of COVID-19 or being hospitalized.   

Correctional facilities are able to order REGEN-COV and bamlanivimab/etesevimab monoclonal antibodies for their facilities. The administration of these COVID-19 therapeutics requires intravenous infusion.  

The program supports multiple distribution models, depending on the needs and infrastructure of respective state/local department of corrections, or equivalent. These models include:

  • Direct shipments to facilities with on-site capacity to receive, store, prepare, and administer mAbs. 
  • Shipments to contract correctional healthcare providers and/or pharmacies. 
  • Shipments to local pharmacies serving correctional facilities.

Consider becoming
an infusion site

Planning to
Administer mAbs​



Step 1: Consider becoming an Infusion Site

If you are considering having your correctional facility offer COVID-19 mAb therapy, you can quickly evaluate your readiness in three steps: 

  1. Does your facility have the infrastructure to meet the needs for treatment? If not, is your facility prepared to make the required investment changes to be ready? 
  2. Is your current staff able to support outpatient mAb administration? If not, is your facility prepared to add or reassign staff as necessary? 
  3. Are your procedures and processes able to identify and treat eligible COVID-19 patients in an efficient manner and within the 10-day recommended timeframe? If not, is your facility prepared to add to or to adjust relevant procedures and processes?
To learn more about considerations for offering mAbs therapy, check out our guide Becoming a Site to Administer COVID-19 mAb Therapy and the COVID-19 Monoclonal Antibody Therapeutics Calculator for Infusion Sites.

Step 2: Planning for mAbs Administration

Once your correctional facility has decided to offer COVID-19 mAb therapy, your facility will need a plan to carry out the following activities:

  1. Allocate dedicated space and develop a plan to manage patient flow.
        • Develop a clear process for patients that are coming to your clinical site.
        • Design your admission process to minimize risk of spread per facility requirements/directions/guidelines.
        • Designate a dedicated room available for treatment.
  2. Obtain infusion components (IV kits, infusion chair/bed, IV pole, vital sign monitoring equipment, emergency medications).
  3. Assign sufficient personnel to meet the expected demand, which includes having plans in place for nurses/IV techs, physicians, pharmacists, or other licensed medical professionals. You will likely need a dedicated team to treat patients.
  4. Prepare for the drug administration process. The treatment typically takes 16 minutes to one hour and is followed by a one-hour post-treatment observation period.
        • Develop a clear treatment and monitoring plan for the infusion process. 
        • Define emergency protocols for addressing potential infusion reactions or complications. 
        • Define a clear process for patient follow-up, using telemedicine when possible.
  5. Prepare for reporting adverse events and record keeping.
The HHS/ASPR Monoclonal Antibody Infusion Center Model offers detailed information on all aspects of setting up a COVID-19 mAb infusion center at your site, including: facility layout; patient flow, stations, and staffing; supplies; infection control and prevention; and reimbursement.

Step 3: Ordering Product

All sites that meet the requirements for administering monoclonal antibody therapeutics must order  REGEN-COV and bamlanivimab/etesevimab directly from AmerisourceBergen Corporation (ABC), the drugs’ sole distributor. The products remain free of charge to requesting sites. To learn more, see the direct ordering process guide and place orders directly with ABC using the C19 Therapies Direct Order Request system.

Step 4: Tracking Utilization

All sites that use monoclonal antibody therapeutics are required to report on utilization of the product every Wednesday. To learn more about your facility’s reporting requirements, see the process for tracking utilization of COVID-19 therapeutics.

Step 5: Stay up-to-date

HHS / ASPR Office Hours

Join us for informative biweekly sessions to learn more about the administration of COVID-19 mAbs. This meeting is an open forum for state and territorial health officer, health care providers and sites of care to ask us your questions on administration of therapies.

  • Office Call SessionsHHS / ASPR Allocation, Distribution, Administration of COVID-19 Therapeutics
    Thursdays (2:00-2:30PM ET)       
  • State, Local, Tribal, and Territorial Public Health Officials:
    Wednesdays (2:00-2:45PM ET)
  • Healthcare Systems and State Hospital Associations
    Wednesdays (3:15-4:00PM ET)

Please email to request Zoom links for these calls

Project ECHO Clinical Grand Rounds

Project ECHO, in collaboration with ASPR, has launched the Outpatient Therapeutics Mini-Series for clinical overview and examples of administration models This mini-series will provide a deep dive on new and emerging COVID-19 outpatient therapeutics, including monoclonal antibodies. The goal of this mini-series is to equip clinicians with the appropriate knowledge, resources, and tools needed to initiate and scale administration of these therapies and reduce strain on the U.S. healthcare system.

Button Learn About Previous Sessions

Related Pages


For Providers
Button for providers

For Patients
Button for patients

Infusion Sites
Button infusion sites

  • This page last reviewed: July 07, 2021